Marco Leitzke | immunology | Best Researcher Award

Published on by Cell Biologist

Dr. Marco Leitzke | immunology | Best Researcher Award

Dr. Marco Leitzke, Helios clinics, Germany

Dr. Marco Leitzke, born in 1970 in Karl-Marx-Stadt, Germany, is a senior anesthesiologist and pioneering researcher in neuromodulation and post-viral syndromes. He has served as Senior Consultant in Anesthesiology and Intensive Care at Helios Clinic Leisnig since 2015 and has extensive experience in pain therapy and palliative medicine. Renowned for his innovative studies on autonomic dysfunction, Dr. Leitzke has published extensively on cholinergic neurotransmission, COVID-19 coagulopathy, and vagus nerve stimulation. His recent focus on Long COVID as a disorder of disrupted acetylcholine signaling has gained significant scientific attention. With a dual career in clinical practice and experimental research, he bridges the gap between bedside and bench. His work earned him accolades, including a Poster Award at the 1st Long COVID Congress in Jena. Passionate about translational medicine, Dr. Leitzke continues to drive forward the understanding and treatment of complex neuroimmune disorders.

Publication Profile: 

Google Scholar

Scopus

Education:

Dr. Leitzke’s medical education and specialization reflect a deep commitment to anesthesiology and neurobiological research. He became a board-certified specialist in anesthesiology in 2006 and has built on this foundation with focused training in advanced pain management, ultrasound-guided interventions, and emergency medicine. He undertook specialized pain therapy training in 2015 and interventional pain techniques in 2014. In 2019, he began training as an Antibiotic Stewardship (ABS) expert physician, further demonstrating his holistic approach to patient safety and infection control. He also completed a transthoracic echocardiography course in 2018, showcasing his commitment to continuous learning and cross-disciplinary skills. This diverse academic background provides the basis for his translational research into neuroimmune and autonomic disorders, with a strong emphasis on clinical application. His combination of anesthesiology, ultrasound, pain therapy, and experimental neurobiology positions him as a uniquely skilled researcher bridging clinical practice and neuroscience.

Experience:

Dr. Marco Leitzke brings over two decades of clinical experience, predominantly in anesthesiology, intensive care, pain therapy, and palliative medicine. Since 2015, he has held the position of Senior Consultant at the Helios Clinic in Leisnig, where he leads interdisciplinary efforts in patient care and clinical innovation. Prior to this, he served as Senior Consultant at Asklepios Clinic Weißenfels from 2011 to 2014, while also operating as a freelance physician in Zeitz. His professional focus spans acute and chronic pain, complex anesthesia procedures, and critical care management, underpinned by a solid emergency medicine foundation gained since 2001. His hands-on experience with ultrasound-guided interventions, vagal modulation therapies, and autonomic diagnostics directly informs his research into the pathophysiology of post-viral syndromes. The integration of clinical insight and scientific exploration marks him as a dual-domain expert, fostering new therapeutic approaches rooted in both laboratory evidence and patient outcomes.

Research Focus:

Dr. Leitzke’s research centers on cholinergic neurotransmission and its impairment in acute and chronic post-viral conditions, particularly Long COVID. His central hypothesis suggests that autonomic dysfunction and neuromodulatory imbalance—specifically, disruption of the vagus nerve and acetylcholine pathways—underlie many post-viral symptoms. Through translational models using animal studies and human imaging, he explores therapeutic modulation, including vagal nerve stimulation and nicotine administration, to restore autonomic balance. His research extends to the role of NF-κB activation in COVID-19-associated coagulopathy, suggesting molecular pathways that link inflammation, clotting, and neuroimmune dysfunction. A hallmark of his work is the use of advanced imaging techniques (e.g., PET scans) to quantify cerebral receptor activity, particularly α7 nicotinic acetylcholine receptors. This integrative and experimental approach offers new perspectives on diagnostics and treatment in neuroimmune conditions, making his work highly relevant to both the scientific and medical communities in the era of post-COVID syndromes.

Publications Top Notes:

  1. 📖 Long COVID – A Critical Disruption of Cholinergic Neurotransmission? (Springer Nature, 2025)

  2. 📖 Is the Post-COVID-19 Syndrome a Severe Impairment of Acetylcholine-Orchestrated Neuromodulation That Responds to Nicotine Administration? (Springer Nature, 2023)

  3. 🏅 COVID-19 – The Ultimate NF-κB Rush and the Crucial Importance of Nicotinic Acetylcholine Receptors (Poster Award, Long COVID Congress, 2022)

  4. 🔬 Experimental Design for PET Detection of α7nAChR Under Gastric Vagus Nerve Stimulation in Piglets (DAS PLUS AN SCHUTZ, 2022)

  5. 🧠 The Viral Accelerated NF-κB Pathway and COVID-19-Associated Coagulopathy – A Case Report (Fortune Journals, 2021)

  6. 🧪 Afferent Vagal Stimulation via Gastric Electrical Stimulation Alters Sympathetic-Vagal Balance in Pigs – A Pilot Trial (Journal of Biological Regulators, 2021)

  7. ⚖️ Autonomic Balance Determines the Severity of COVID-19 Courses (Springer Nature, 2020)

  8. 🧮 A Semi-Automated Algorithm for Hypothalamus Volumetry in 3 Tesla MRI (Psychiatry Research: Neuroimaging, 2018)

  9. 🧬 Image-Derived Input Function for (-)-[18F]Flubatine Using a Digital PET System (European Journal of Nuclear Medicine, 2024)

  10. 💊 What Is the Impact of Nicotine on the Post-COVID-19 Syndrome? – A Case Series (Preprint, 2025)

Conclusion:

Dr. Marco Leitzke is a highly deserving candidate for the Best Researcher Award due to his pioneering contributions to understanding and treating Long COVID and neuroimmune disorders. His strong publication record, interdisciplinary approach, and clinical insight mark him as a leading figure in his field. With enhanced international collaboration and clinical validation of his findings, his impact could be even greater. Overall, his research is timely, innovative, and of substantial scientific and societal importance.

Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Published on by Cell Biologist

Dr. Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Dr. Herbeuval Jean-Philippe | CNRS | France

Jean-Philippe Herbeuval is a French immunologist and CNRS Director of Research, renowned for pioneering contributions to translational immunology and biomedical innovation. A PhD holder in immuno-oncology, he completed a prestigious Fogarty Fellowship at the NIH, USA, where he earned the Norman P. Salzman Award. He founded and leads the CBMIT team at Université Paris Cité, integrating immunology, virology, and chemistry for therapeutic discovery. Herbeuval has launched two biotech companies: Ermium Therapeutics, based on anti-interferon therapies, and Elyris Pharma, centered on PDK1 as a novel anti-inflammatory target. With 9 patents (3 licensed), €8.8M in research funding, and >70 publications (h-index 28), his innovations span diagnostics to therapeutics. He also contributes to policy and innovation strategy through national and international committees. Recognized for his vision, leadership, and mentorship, Herbeuval exemplifies the intersection of academic research and impactful biotechnology entrepreneurship.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Exceptional Innovation in Immunology & Therapeutics

    • Discovered key therapeutic targets such as CXCR4 and PDK1.

    • Founded Ermium Therapeutics (2019) and Elyris Pharma (2024), securing over €12M in funding.

    • Holds 9 patents, with 3 already licensed — a key indicator of translational success.

  2. Proven Scientific Leadership

    • Director of Research (CNRS), Head of CBMIT at Université Paris Cité.

    • Established and led multiple interdisciplinary research teams and platforms (Cyto2BM, CBMIT).

    • Supervised 10 PhD students, 7 postdocs, and over 18 master’s students, many of whom reached elite positions.

  3. High-Impact Research Output

    • 70+ publications, including high-citation studies on interferon signaling in HIV.

    • Over 3,500 citations, h-index: 28 — showing strong impact and visibility.

  4. Strong National and International Recognition

    • Winner of the prestigious i-Lab National Innovation Prize (France, 2019).

    • Invited speaker at over 24 international conferences; reviewer for Nature Medicine and PNAS.

    • Advisor for funding agencies across the US (NIH), UK (MRC), China, and Brazil.

  5. Valuable Public and Government Engagement

    • CNRS Innovation Ambassador (2024) and expert for multiple national programs (ANRS, Campus France).

    • Actively engages in public science communication (TV, radio, press).

🔧 Areas for Improvement:

  1. Scaling Global Industry Impact

    • While Ermium and Elyris are high-potential, further proof of market adoption and therapeutic success will solidify his innovation leadership globally.

  2. Broader Patent Commercialization

    • More patents could potentially be moved from licensing to full-scale clinical trials or product development phases.

  3. Diversity of Therapeutic Areas

    • While the focus on interferon biology and immunomodulation is powerful, broader expansion into other disease domains (e.g., neuroinflammation, metabolic syndromes) could enhance reach.

🎓 Education:

Jean-Philippe Herbeuval earned his PhD in immuno-oncology in 2001 from Université Jean Monnet, Saint-Étienne, working under the INSERM network. He then pursued a highly competitive five-year Fogarty Postdoctoral Fellowship at the National Institutes of Health (NIH), USA, under Dr. Gene Shearer, focusing on the antiviral response to HIV. During this time, he earned multiple prestigious awards including the Norman P. Salzman Award and an NIH Young Scientist Cash Award. Upon returning to France, he secured a CNRS Junior PI position in 2006 and received his Habilitation to Direct Research (HDR) in 2008 from Université Paris Descartes. His rapid career progression continued with his appointment as Director of Research (2nd class) in 2013 and promotion to 1st class in 2019 at CNRS UMR8601. His educational path reflects an exceptional blend of scientific rigor, international exposure, and leadership in innovation.

💼 Experience:

Jean-Philippe Herbeuval brings over two decades of distinguished experience at the interface of academic research and biotech innovation. Starting with his postdoctoral fellowship at NIH (2001–2006), he led groundbreaking studies on interferon responses in HIV. Since 2006, he has served within CNRS, creating and leading the CBMIT interdisciplinary team. He established the Cyto2BM core facility and spearheaded multiple translational projects. As scientific founder of Ermium Therapeutics (2019) and Elyris Pharma (2024, in progress), he has successfully attracted venture capital and secured technology transfer agreements. His strategic involvement extends to national innovation committees (ANRS, CNRS, Campus France) and advisory roles. He has trained over 35 researchers and supervised major national/international grants. Notably, he combines deep scientific insight with an entrepreneurial mindset, as shown by his participation in Deeptech Founders and RISE programs. His experience spans leadership, translational science, investment negotiations, and scientific mentoring.

🔬 Research Focus:

Jean-Philippe Herbeuval’s research is centered on translational immunology, particularly type I interferons, autoinflammatory pathways, and host-pathogen interactions. His work explores immune dysregulation in infectious diseases such as HIV, SARS-CoV-2, dengue, and influenza, with a special focus on the immune-modulatory roles of dendritic cells and apoptotic pathways. He has identified novel therapeutic targets including CXCR4 and PDK1, leading to two biotech start-ups and multiple patents. His interdisciplinary CBMIT team integrates immunology, virology, medicinal chemistry, and computational modeling to develop innovative therapeutic strategies and biomarkers. He has a keen interest in immunomodulation, therapeutic interference with IFN pathways, and discovery of druggable checkpoints in innate immunity. With over 70 peer-reviewed publications, his scientific output has shaped current understanding of immune pathogenesis and opened new avenues for therapy in inflammatory and infectious diseases. His approach bridges fundamental research with practical applications in drug discovery and biotech development.

📚 Publications Top Notes:

  1. 🧬 HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

  2. ⚰️ CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon–dependent, TRAIL/DR5-mediated apoptosis

  3. 🚻 Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women

  4. 🧪 HIV-1 immunopathogenesis: how good interferon turns bad

  5. 🔄 Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

  6. 🧠 Differential expression of IFN-α and TRAIL/DR5 in lymphoid tissue of progressor vs. nonprogressor HIV-1-infected patients

  7. 🧟 HIV turns plasmacytoid dendritic cells into TRAIL-expressing killer pDC via TLR7-induced IFN-α

  8. 🧬 Regulation of TRAIL on primary CD4+ T cells by HIV-1: role of plasmacytoid dendritic cells

  9. 💉 TRAIL in HIV-1–infected patients and its production by antigen-presenting cells

  10. 🧫 Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6

🧾 Conclusion:

Dr. Jean-Philippe Herbeuval stands out as a highly qualified and deserving candidate for the Best Innovator Award. His rare combination of scientific excellence, translational innovation, entrepreneurial leadership, and mentorship places him in the top tier of biomedical innovators. His work not only bridges science and industry but also directly contributes to addressing global health challenges. Continued support and recognition of his efforts will likely catalyze further innovation in therapeutic immunology.

Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Dr. Fani Pantouli, Cleveland Clinic Florida Research and Innovation Center, United States

Dr. Fani Pantouli is a passionate and results-driven research scientist with deep expertise in neuroscience, pharmacology, immunology, and oncology. A USA permanent resident, she currently serves as a Postdoctoral Fellow at the Cleveland Clinic Florida Research and Innovation Center. Her work bridges cutting-edge vaccine development and cancer therapeutics, contributing significantly to preclinical and translational research. Dr. Pantouli’s scientific approach blends in vivo and in vitro techniques to uncover therapeutic pathways, particularly in head and neck cancer and viral immunology. Her interdisciplinary knowledge is reflected in a growing portfolio of peer-reviewed publications addressing pressing biomedical challenges, from COVID-19 immunity to neuropsychiatric disorders. She is known for her innovative methodologies, collaborative mindset, and unwavering dedication to advancing human health. Dr. Pantouli’s work is making a meaningful impact on personalized medicine and translational therapeutics, positioning her as a rising leader in biomedical research.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Multidisciplinary Expertise
    Dr. Pantouli integrates neuroscience, immunology, pharmacology, and oncology into her research, making her contributions uniquely cross-disciplinary and impactful.

  2. High-Impact Research in Vaccine Development
    Her postdoctoral work on COVID-19 and respiratory viruses, particularly her development of T-cell profiling and viral neutralization assays, directly informs global efforts in personalized vaccine design.

  3. Innovative Cancer Models
    She developed a novel in vivo murine model for head and neck squamous cell carcinoma, advancing drug screening for p53-related targets. This is vital in understanding and treating cancers with p53 mutations.

  4. Robust Publication Record
    Dr. Pantouli has authored or co-authored multiple peer-reviewed articles in reputable journals (e.g., Vaccines, Neuropsychopharmacology), with several under review in top-tier outlets like Science and Journal of Biological Psychiatry.

  5. Focus on Health Equity
    Her research into ethnic differences in immune response underscores a strong commitment to inclusive and equitable healthcare.

  6. Experience in Preclinical & Translational Research
    Her hands-on experience building disease models and testing therapeutic strategies bridges basic science and clinical application—core to translational medicine.

⚠️ Areas for Improvement:

  1. Independent Research Leadership
    While she has made significant contributions as a postdoctoral fellow, moving toward independent investigator roles (e.g., PI on grants) would strengthen her candidacy.

  2. Visibility and Recognition
    Increased presence in international symposia, keynote talks, or award recognitions would help boost her visibility within the scientific community.

  3. Mentorship and Community Involvement
    Involvement in mentoring junior researchers or leading educational outreach initiatives could further showcase her leadership potential.

🎓 Education:

Dr. Pantouli holds a Ph.D. in Neuropharmacology from the University of Surrey and St. George’s University of London, awarded between 2014 and 2017. Her doctoral studies explored neural mechanisms underpinning pharmacological and behavioral outcomes, laying a solid foundation for her current work in translational medicine. Prior to her Ph.D., she completed an MSc in Molecular Neuroscience from the University of Bristol in 2011, where she specialized in neurodevelopmental and degenerative disorders. Her undergraduate studies were completed at the University of Bedfordshire in 2010, where she earned a BSc (Hons) in Biomedical Science. Dr. Pantouli’s academic trajectory reflects a commitment to interdisciplinary learning and a focus on brain and immune system interactions. Her education combines rigorous training in molecular biology, pharmacology, and neuroscience, empowering her to address complex biomedical questions with a systems-level perspective.

🧪 Experience:

Dr. Pantouli is currently a Postdoctoral Fellow in Vaccine Development Research at the Cleveland Clinic Florida Research and Innovation Center (June 2023 – Present), where she investigates T cell immune responses and develops viral neutralization assays for respiratory viruses including SARS-CoV-2. Previously, she was a Postdoctoral Fellow in the Cancer Research Lab at the same institute (January 2022 – June 2023), where she created innovative murine models of head and neck cancer to evaluate therapeutic efficacy targeting mutant p53. Her research integrates advanced in vivo systems and immune profiling to enhance drug discovery and vaccine evaluation. With a decade-long track record across academia and clinical research centers, Dr. Pantouli has developed robust platforms for translational research, immunotherapeutics, and precision medicine. Her skills span experimental design, animal modeling, immunoassays, and bioanalysis, equipping her to tackle critical gaps in infectious disease and oncology treatment strategies.

🔬 Research Focus:

Dr. Pantouli’s research is centered on translational medicine, focusing on vaccine development, immunotherapy, and molecular pharmacology. Her current projects address immune modulation in viral infections, especially COVID-19, and the development of preclinical assays for vaccine and drug evaluation. She also leads research in oncology, particularly targeting p53 mutations in head and neck squamous cell carcinoma using in vivo models. Her earlier academic work examined the neural and behavioral effects of neuropeptides and receptor modulators in models of autism and Fragile X Syndrome, showing a consistent interest in neuroimmune interactions. She employs a multidisciplinary approach—blending pharmacological, molecular, and immunological tools—to explore how targeted therapies can be optimized for diverse populations. Her work is vital for advancing personalized medicine, especially for aging populations and ethnically diverse cohorts, where vaccine efficacy and immune response can differ significantly.

📚 Publications Top Notes:

  • 🧫 Ethnic differences in COVID-19 T cell immunity responses across variants from Wuhan to Omicron – Accepted in Vaccines

  • 🧠 Evaluation of SR-17018 and oxycodone in the conditioned place preference paradigm using peanut butter chip vehicle – In preparation, Neuropharmacology

  • 🧬 Generation of antigen-specific paired heavy-light chain antibody sequences using large language models – Submitted to Science

  • 💉 COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly – Vaccines (2025)

  • 🧩 Tilted striatofugal balance and mGluR4 modulation in the Fmr1 mouse model of Fragile X Syndrome – Under review, Journal of Biological Psychiatry

  • 👃 Acute, chronic and conditioned effects of intranasal oxytocin in mu opioid receptor knockout mice: social context matters – Neuropsychopharmacology (2024)

🧾 Conclusion:

Dr. Fani Pantouli is a highly promising and impactful scientist whose research spans some of the most critical health challenges of our time—infectious diseases, cancer, and neurodevelopmental disorders. Her technical expertise, innovative model development, and deep understanding of immune and neural systems make her an excellent nominee for the Best Researcher Award.

Miriam Götte | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Miriam Götte | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Miriam Götte , Westdeutsches Tumorzentrum, Universitätsklinikum Essen , Germany

Dr. Miriam Götte is a leading expert in exercise and movement science in oncology, currently affiliated with the University Hospital Essen. With a dedicated focus on pediatric and young adult cancer care, she has led numerous interdisciplinary initiatives combining sports science, immunology, and oncology. As head of the Working Group on Sports and Movement Therapy at the West German Tumor Center, she has pioneered therapeutic interventions improving the quality of life in cancer patients. Dr. Götte holds a habilitation in Movement Science in Oncology and has been a postdoctoral researcher since 2014. Her work has been recognized nationally and internationally through prestigious awards. Passionate about improving survivorship care, she integrates clinical research, physical rehabilitation, and academic leadership. Alongside her academic career, she balances motherhood, having taken two parental leaves, which reflects her ability to manage demanding roles in both personal and professional spheres.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. 🌍 Leading Expertise in Exercise Oncology: Dr. Götte has made outstanding contributions to the field of exercise-based interventions in pediatric and adolescent oncology, a highly impactful and emerging research domain.

  2. 📊 Rich and Relevant Research Output: With over 10 peer-reviewed publications in top-tier journals (2023–2024 alone), she is actively contributing novel data, especially around HIIT, immune response, stem cell transplantation, and survivorship care.

  3. 👩‍🔬 Translational Focus with Real-World Impact: Her work bridges clinical research and applied therapy, ensuring that findings benefit patient quality of life and recovery during and after cancer treatment.

  4. 🤝 National Leadership and Collaborations: As Head of the Working Group on Sports and Movement Therapy and a core member of the ActiveOncoKids Network, she leads national initiatives and cross-border collaborations.

  5. 🏆 Recognized with Prestigious Awards: Awards such as the MASCC Young Investigator Award (2015) and Best Abstract at ASORS (2017) reflect her high academic standing and the relevance of her research.

  6. 📚 Interdisciplinary Approach: Combining sports science, immunology, pediatrics, and education, she exemplifies a multidisciplinary perspective that advances both research and therapeutic care.

⚙️ Areas for Improvement:

  1. 📣 Global Visibility: While well-known in German-speaking countries and European forums, increasing participation in global oncology or exercise medicine symposia (e.g., ASCO, ACSM) would raise international recognition.

  2. 💼 Expanded Mentorship: Publishing with more junior researchers as first authors could further support the next generation and solidify her legacy as a mentor in her field.

  3. 🌐 Broader Public Engagement: Developing online modules, webinars, or patient-facing tools (especially for young survivors) could enhance public awareness and dissemination of her impactful work.

🎓 Education:

Dr. Miriam Götte has a solid academic background in sports and medical sciences. She began her academic journey studying Sports Science with a focus on prevention and rehabilitation at the University of Cologne from 2006 to 2010. During this period, she also pursued studies in Educational Sciences. She advanced to a doctoral program in Medical Sciences at the University of Duisburg-Essen, completing it between 2010 and 2014 under the mentorship of Prof. Dr. Dirk Reinhardt. Her academic accomplishments culminated in a habilitation in “Movement Science in Oncology” at the Medical Faculty of the University of Duisburg-Essen in 2022. This advanced qualification marks her as an expert in the interplay of exercise and oncology, particularly for pediatric and adolescent populations. Her academic path has been underpinned by a strong interdisciplinary approach, combining sports science, oncology, and education to support patients holistically.

💼 Experience:

Dr. Götte’s professional journey began at the Department of Pediatrics III, University Hospital Essen, where she worked from 2010 to 2014 during her doctoral training. She later became head of Sports and Exercise Therapy at the West German Tumor Center (2014–2017) and continued in leadership roles at the same institution until July 2023. Since January 2023, she has served as head of the Working Group on Sports and Movement Therapy in Oncology, playing a pivotal role in the ActiveOncoKids Center Ruhr. Dr. Götte also coordinated teacher training modules in Spanish and led national collaborations to develop exercise strategies during cancer treatment. She has taken two parental leaves (2017–2018 and 2023–2024), highlighting her balance between research and personal life. Her hands-on leadership in multi-center projects and her dedication to integrating physical activity into oncology care make her a driving force in supportive cancer therapy.

🏆 Awards and Honors:

Dr. Miriam Götte has received numerous awards recognizing her impactful research and leadership. She was honored with the Young Investigator Award of the Year at the MASCC/ISOO Annual Meeting on Supportive Care in Cancer in 2015. Her work on adolescent cancer care earned the Best Abstract Award at the 5th ASORS Congress in 2017. She was selected for the prestigious Josepha and Charlotte von Siebold Habilitation Support Program (2018–2019), and later received support from the Corona Care in Medicine Program (2020–2021) by the Medical Faculty of the University of Duisburg-Essen. These accolades underline her academic excellence and leadership in movement science and oncology. Dr. Götte’s pioneering research continues to shape exercise-based cancer therapy, especially for children and adolescents, earning her national and international recognition as a forward-thinking clinician-scientist.

🔬 Research Focus:

Dr. Miriam Götte’s research revolves around exercise oncology, with a strong emphasis on pediatric and adolescent cancer patients. Her primary interest lies in exploring how physical activity interventions, particularly high-intensity interval training (HIIT), influence immune function, physical fitness, and quality of life during and after cancer therapy. She investigates the physiological and psychological impacts of exercise throughout different treatment phases, including stem cell transplantation. Her work contributes significantly to the emerging field of supportive oncology, where movement-based interventions are tailored to patient needs. Dr. Götte is also a central figure in the ActiveOncoKids network, enhancing access to structured physical activity across German-speaking countries. With a translational approach, her research bridges clinical care, immunological assessments, and rehabilitative exercise programs. Her focus is not only scientific but also deeply patient-centered, advocating for movement as a form of healing and empowerment in cancer survivorship.

📚 Publications Top Notes:

  1. 🏋️‍♂️ High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls – Cancer Medicine (submitted)

  2. 🧬 Impact of a Single HIIT Session on NK Cells and ILCs in Adolescents Undergoing Cancer Treatment – BMC Cancer (minor revision)

  3. 🌟 YOUEX: Longitudinal Effects on Quality of Life in Young Adults with Cancer – JAYAO (submitted)

  4. 💪 Low vs. Moderate Intensity Exercise in Pediatric Allo-HSCT Recovery – ANIMAL – Pediatric Blood & Cancer (submitted)

  5. 👶 Physical Activity Behaviors in Childhood Cancer Survivors – J Cancer Survivorship (2024)

  6. 🧒 ActiveOncoKids: Centralized Physical Activity Counseling During Oncology – Klinische Pädiatrie (2024)

  7. 🏃 Severely Reduced Physical Performance at Stem Cell Transplant Admission – BMJ Open Sport Exerc Med (2024)

  8. 🧘 P-move: RCT of Exercise in Pancreatic or Biliary Tract Cancer – Supportive Care in Cancer (2024)

  9. 🌿 Exercise Therapy in Oncology: Impact on Quality of Life and Side Effects – Dtsch Arztebl Int (2024)

  10. 🧑‍⚕️ Adaptation of Pediatric Exercise Programs During COVID-19 in Germany – Frontiers in Pediatrics (2024)

🧾 Conclusion:

Dr. Miriam Götte is highly suitable and deserving of the Best Researcher Award. Her focused and prolific research on the role of physical activity in pediatric and adolescent oncology, combined with her leadership in clinical and academic settings, sets her apart as a pioneer in supportive cancer care. She demonstrates a rare combination of scientific rigor, patient-centeredness, and organizational leadership. With strategic expansion of her international visibility and mentoring activities, she is positioned to become one of the global leaders in exercise oncology.

Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Mr. Muhammad Junaid Anwar , Bahauddin Zakariya Univeristy Multan Pakistan , Pakistan

Dr. Muhammad Junaid Anwar is a dedicated food scientist specializing in Food Science and Technology. With a Ph.D. from Bahauddin Zakariya University (BZU), Multan, he has established himself as a researcher with expertise in food safety, nanotechnology, and functional foods. His work focuses on developing innovative solutions for food security, nutrition, and disease prevention. Having authored multiple high-impact research publications, Dr. Anwar’s contributions span across nanotechnology-based food encapsulation, food safety enhancement, and alternative protein sources. He has also participated in prestigious conferences and workshops, further showcasing his commitment to advancing food science. His research has significantly contributed to tackling food-related health challenges such as cow milk allergies, microbial contamination, and nutraceutical applications. With his profound knowledge, industry experience, and research excellence, Dr. Anwar stands out as a promising scholar in the field. His dedication to food innovation makes him a deserving candidate for the Best Researcher Award.

Publication Profile: 

Scopus

Strengths for the Award

  1. Strong Academic Background – Dr. Muhammad Junaid Anwar has an exceptional academic record with a Ph.D. in Food Science and Technology, a strong CGPA, and an extensive research focus.

  2. High-Impact Research Publications – He has authored multiple research articles in reputable, high-impact factor journals (Ultrasonics Sonochemistry, Food Science & Nutrition, Food Bioscience, etc.). His contributions cover diverse areas, including nanotechnology, food safety, and immunomodulation.

  3. Diverse Research Contributions – His research spans crucial topics such as nano-encapsulation, diabetes management, functional foods, and nutraceuticals, demonstrating interdisciplinary expertise.

  4. Industry Experience – His experience as an Officer in Quality Enhancement and Laboratory at S.M. Food Makers highlights his applied knowledge and practical contribution to food science.

  5. Conference Participation – He has actively contributed to scientific discussions through multiple national conferences, particularly on food security and food safety.

  6. Published Abstracts & Workshops – His engagement in published abstracts and workshops reflects an effort to bridge academia with real-world food technology applications.

Areas for Improvement

  1. International Collaboration – While his research is strong, expanding collaborations with international institutions and researchers could further enhance global impact.

  2. Patent & Commercialization – Translating research into patents or commercial food innovations would strengthen his practical contributions to the industry.

  3. Citations & Recognition – As some of his latest research articles have yet to gain citations, increasing visibility through academic networks and outreach can boost recognition.

Education:

Dr. Muhammad Junaid Anwar has an exceptional academic background in Food Science and Technology. He is currently completing his Ph.D. (2021-2025) at the Department of Food Science and Technology, BZU Multan, with a stellar CGPA of 3.87/4.00. Previously, he completed his M.Sc. (Hons.) in Food Science & Technology (2018-2020) from the same institution, securing a CGPA of 3.76/4.00. His undergraduate journey began with a B.Sc. (Hons.) in Agriculture (Food Science & Technology) (2014-2018), again with a CGPA of 3.76/4.00. His solid foundation in sciences started with F.Sc. (Pre-Medical) in 2014 from Muslim Public Higher Secondary School, Multan, achieving 840/1100 marks, followed by Matriculation in 2012 from Govt. M.A Jinnah High School, Multan, with 863/1050 marks. His consistent academic excellence highlights his dedication to food science research and technological advancements, making him a strong candidate for the Best Researcher Award.

Experience:

Dr. Muhammad Junaid Anwar has a diverse professional background in food science research and industry. He completed a 7-week internship at Bunny’s Limited, Lahore, where he gained hands-on experience in food processing and quality control. He later served as an Officer (Quality Enhancement and Lab) at S.M. Food Makers for two years (2018-2020), where he worked on ensuring food safety standards and enhancing product quality. His industry experience has provided him with a deep understanding of food technology applications, quality assurance, and research methodologies. In addition to his industry roles, he has contributed to academia through extensive research on food nanotechnology, functional foods, and microbial safety. His experience spans both applied and theoretical research, making him an asset to the food science community. His professional achievements, combined with his research excellence, make him a strong contender for the Best Researcher Award.

Research Focus:

Dr. Muhammad Junaid Anwar’s research revolves around food nanotechnology, functional foods, and food safety. His recent work focuses on the nano-encapsulation of bioactive compounds, such as casein-based encapsulation for managing cow milk allergies. His contributions extend to food safety enhancements using ultrasonication and calcium chloride treatments to reduce microbial contamination in fresh produce. Dr. Anwar has also explored the nutraceutical applications of medicinal plants like fenugreek and Tribulus terrestris to develop functional foods with health benefits. His studies have highlighted the role of alternative protein sources, such as Moringa oleifera-derived proteins, in plant-based meat substitutes. Additionally, he has worked on the impact of ozone treatment in mitigating mycotoxin contamination in food. His multi-disciplinary approach to food science integrates biotechnology, food engineering, and health sciences, making his research valuable for global food security and human health. His outstanding contributions make him a strong candidate for the Best Researcher Award.

Publications Top Notes:

📌 Casein-Based Nano-Encapsulation for Cow Milk Allergy Management 🥛🔬 (Food Bioscience, 2025)
📌 Ultrasonication & Calcium Chloride Pre-Treatment for Microbial Load Reduction in Carrots 🥕🦠 (Ultrasonics Sonochemistry, 2025)
📌 Isoflavones: Natural Agents for Cancer Prevention & Treatment 🎗️🍃 (Food Science & Nutrition, 2025)
📌 Functional Yogurt with Cinnamon & Stevia for Diabetes Management 🍦🍯 (Food & Agricultural Immunology, 2024)
📌 Nutritional & Physico-Chemical Profiling of Tribulus terrestris for Nutraceutical Applications 🌿💊 (Journal of Population Therapeutics & Clinical Pharmacology, 2024)
📌 The Multifaceted Potential of Fenugreek Seeds in Health & Nanotechnology 🌱⚗️ (Food Science & Nutrition, 2024)
📌 Protein Extraction from Moringa Leaves as a Plant-Based Meat Alternative 🍃🥩 (Regulatory Toxicology & Pharmacology, 2024)
📌 Role of Ozone in Mycotoxin Management for Food Safety ⚡🍞 (PSFST Conference, 2023)
📌 Potential of Anaerobic Digestion in Food Waste Management 🔄♻️ (PSFST Conference, 2023)
📌 Addressing Food Price Fluctuations: A Global Priority 📈🌍 (PSFST Conference, 2023)
📌 Strengthening Local Food Systems for Food Security 🌾🍽️ (PSFST Conference, 2023)

Conclusion:

Dr. Muhammad Junaid Anwar has demonstrated exceptional research contributions in food science, particularly in functional foods, nanotechnology, and food safety. His high-impact publications, active participation in conferences, and industry experience make him a strong candidate for the Best Researcher Award. Strengthening international collaborations and focusing on patents or commercialization could further enhance his research impact.